Skip to content
AnalystLens

ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 22, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed January 22, 2025
Period End
January 22, 2025
Security
ABT
In the record · 2016–202610-K1110-Q328-K131

ABT filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 131 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Feb ’17Feb ’17
  2. Material agreement8-K · Nov ’18Nov ’18
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Apr ’26Apr ’26

01—Abstract

Summary

Summary of the 8-K filed January 22, 2025. Cited figures are marked; the original filing is the authoritative source.

Abbott Laboratories reported fourth-quarter 2024 sales of $11.0 billiona, up 7.2% reported and 10.1% organic excluding COVID-19 testing, with full-year 2024 sales of $42.0 billion (up 4.6% reported, 9.6% organic excluding COVID-19 tests).

Growth was led by Medical Devices (Q4 sales up 13.7%, with Diabetes Care and continuous glucose monitors, including FreeStyle Libre, driving results), while Diagnostics was pressured by lower COVID-19 testing demand and Established Pharmaceuticals and Nutrition grew modestly. Full-year adjusted diluted EPS was $4.67b, at the upper end of initial guidance, while GAAP diluted EPS of $7.64 was inflated by a $7.497 billion non-cash tax valuation allowance release tied to restructuring of certain foreign affiliates. Investors should focus on the large gap between GAAP and adjusted results.

The GAAP tax line was a benefit of $6.4 billionc, producing a Q4 GAAP tax rate of -354.6%, versus an adjusted rate of about 15%. The adjusted figures exclude $1.878 billion of intangible amortization and about $755 million of other net expenses (impairments, restructuring, acquisition and divestiture items) for the full year. The GAAP EPS figure should therefore not be used as a run-rate measure of earnings power.

For 2025, Abbott guided to organic sales growth of 7.5% to 8.5%, an adjusted operating margin of 23.5% to 24.0% (about 150 basis points of expansion at the midpoint), and adjusted diluted EPS of $5.05 to $5.25d, implying double-digit growth at the midpoint. First-quarter 2025 adjusted EPS guidance is $1.05 to $1.09. The company also declared its 404th consecutive quarterly dividend of $0.59 per share, payable February 14, 2025, and noted 53 consecutive years of dividend increases.

02—Key points

Key Highlights

  1. Q4 2024 reported sales of $10.974B (+7.2%), organic +8.8%, or +10.1% excluding COVID-19 testing; full-year sales of $41.95B (+4.6%).
  2. Medical Devices was the growth engine: Q4 sales +13.7% reported to $5.05B, with Diabetes Care up 20.1% and continuous glucose monitor sales of $1.8B growing about 22.7%.
  3. Diagnostics declined on COVID-19 testing roll-off (Q4 COVID test sales of $176M vs. $288M a year earlier), though Rapid Diagnostics respiratory testing was strong excluding COVID.
  4. GAAP diluted EPS of $7.64 for FY2024 includes a $7.497B non-cash tax valuation allowance adjustment; adjusted EPS of $4.67 (+5.2%) reached the upper end of initial guidance.
  5. 2025 guidance: organic sales growth of 7.5%–8.5%, adjusted operating margin of 23.5%–24.0%, and adjusted diluted EPS of $5.05–$5.25.
  6. Q1 2025 adjusted EPS guidance of $1.05–$1.09, implying the company's expected near-term trajectory.
  7. Quarterly dividend of $0.59 declared (404th consecutive quarter), with 53 consecutive years of dividend increases; Abbott is an S&P 500 Dividend Aristocrat.

03—Questions

Frequently Asked Questions

  1. Why is GAAP EPS so much higher than adjusted EPS for 2024?

    GAAP net earnings of $13.4B include a $7.497B non-cash tax benefit from valuation allowance adjustments tied to restructuring certain foreign affiliates and confirming tax filing positions. Adjusted results exclude this benefit along with $1.878B of intangible amortization and about $755M of other net expenses, leaving adjusted FY2024 EPS of $4.67 versus GAAP EPS of $7.64.

  2. How did Abbott perform against its 2024 guidance?

    Abbott achieved the upper end of its initial 2024 guidance ranges for both organic sales growth (9.6% excluding COVID-19 tests) and adjusted EPS ($4.67), according to the company.

  3. What is driving 2025 expectations?

    Management expects 7.5%–8.5% organic sales growth and about 150 basis points of adjusted operating margin expansion at the midpoint. The company cites continued momentum in Medical Devices, including Diabetes Care, Structural Heart, and Electrophysiology, plus more than 15 new growth opportunities from its R&D pipeline announced in 2024.

  4. Is the COVID-19 testing decline a long-term concern?

    Abbott describes COVID-19 as having moved to an endemic state, with significantly lower test demand. Full-year COVID test sales fell to $747M from $1.586B in 2023, and Abbott excludes these sales from its underlying base business growth metrics, so the decline reduces reported growth without signaling weakness in the core business.

  5. Is the dividend safe?

    Abbott declared a $0.59 quarterly dividend payable February 14, 2025, and has raised its dividend for 53 consecutive years. The filing does not address payout sustainability directly, but adjusted 2025 EPS guidance of $5.05–$5.25 compared with a $2.36 annualized dividend implies a payout ratio of roughly 45%.

04—Continue

← View all 8-K filings